1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2014 to provide liquidity for tax payments due on account of prior option exercises.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $38.8100 to $39.6950, inclusive.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 above.

/s/ Paul J. Mellett

08/15/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v).